Verifying…
Home / Drug A–Z / Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet

Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet

NAFDAC Reg. No. C4-1797 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet
NAFDAC number
C4-1797
Active ingredient
Montelukast (Montelukast Sodium); Levocetirizine Dihydrochloride
Strength
10 mg; 5 mg
Form
Tablet
Pack size
3 x 10's
Manufacturer
Not listed
Applicant (holder)
Global Organics Ltd
Approved
3 Aug 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
2 Aug 2026
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet is on the NAFDAC register with an active registration (C4-1797). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet is used for

From the official U.S. FDA label for montelukast (montelukast sodium), the active ingredient registered with NAFDAC.

Boxed warning: SERIOUS NEUROPSYCHIATRIC EVENTS WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of montelukast sodium tablets. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). …
What it is used for

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 15 years of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 15 years of age and older, and perennial allergic rhinitis (PAR) in patients 15 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ). Limitations of Use: Not indicated to treat an acute asthma attack ( 5.2 ). …

Possible side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Neuropsychiatric Events [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (incidence ≥ 5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …

Do not use if

Montelukast sodium is contraindicated in patients with hypersensitivity to any of its components. Hypersensitivity to any component of montelukast sodium ( 4 ).

Warnings

Do not prescribe montelukast sodium to treat an acute asthma attack ( 5.2 ). Advise patients to have appropriate rescue medication available ( 5.2 ). Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids ( 5.3 ). Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium ( 5.4 ). Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral corticosteroid therapy ( 5.5 and 6.2 ). …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not established a drug-associated risk of major birth defects [see Data]. …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet

What is in Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet?

Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet contains Montelukast (Montelukast Sodium); Levocetirizine Dihydrochloride (10 mg; 5 mg), as tablet, according to its NAFDAC registration record.

Is Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet registered with NAFDAC?

Yes. Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet is listed on the NAFDAC register under registration number C4-1797, and its registration is active as of 5 November 2026.

Has Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet in our automatically synced alert list.

How can I check that my pack of Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet is genuine?

Run a free authenticity scan with the NAFDAC number C4-1797, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet used for?

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 15 years of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 15 years of age and older, a (Summarised from the official U.S. FDA label for montelukast (montelukast sodium). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Montelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.